BLACKROCK GLOBAL FUNDS BlackRock World Healthscience Fund MAY 2018 FACTSHEET Unless otherwise specified, all information applies to A2 share class in the Fund's base currency only as of the month end. Performance, Top Holdings, Portfolio Breakdowns and Characteristics, and Net Assets as at 31-May-2018. All other data as at 17-Jun-2018. IMPORTANT: The Fund's investments in equities could incur significant losses due to higher fluctuation of equity values. The Fund s investments are concentrated in the healthcare, pharmaceuticals and other healthscience sectors. This may result in greater volatility than more broad-based investments. The Fund is subject to currency risk, emerging market risk, foreign investments restrictions risk, small-cap companies volatility and liquidity risks and securities lending counterparty risk. The Fund may use derivatives for hedging and for investment purposes. However, usage for investment purposes will not be extensive. The Fund may suffer losses from its derivatives usage. The value of the Fund can be volatile and can go down substantially within a short period of time. It is possible that a certain amount of your investment could be lost. Investors should not make investment decisions based on this document alone. Investors should refer to the Prospectus and Key Facts Statement for details including risk factors. INVESTMENT OBJECTIVE RATINGS The World Healthscience Fund seeks to maximise total return. The Fund invests globally at least 70% of its total assets in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. Currency exposure is flexibly managed. GROWTH OF 10,000 FOR PAST 10 YEARS BlackRock World Healthscience Fund A2 USD MSCI World Health Care Index These figures show as a NAV change of the Fund based on a hypothetical 10,000 investment in the share class. CUMULATIVE PERFORMANCE 3 mths 6 mths YTD 1 Year 2 Years 3 Years 5 Years Since Launch Fund (A2 USD) 0.70% 3.13% 2.53% 9.69% 19.07% 8.57% 73.06% 305.30% Benchmark -0.68% 0.12% 0.19% 6.31% 14.58% 7.18% 61.63% 208.69% CALENDAR YEAR PERFORMANCE 2017 2016 2015 2014 2013 Fund (A2 USD) 21.78% -8.02% 4.56% 24.40% 43.09% Benchmark 19.80% -6.81% 6.60% 18.10% 36.27% Morningstar, Inc. All Rights Reserved. KEY FACTS Asset Class Equity Morningstar Category Sector Equity Healthcare Inception Date 06-Apr-2001 Fund Base Currency USD Currency Unhedged:EUR,USD Hedged:AUD,EUR,HKD, SGD Fund Size (mil) 2,912.85 USD Benchmark MSCI World Health Care Index Domicile Luxembourg Fund Type UCITS ISIN LU0122379950 Bloomberg Index Ticker MERHLTA PORTFOLIO MANAGERS Erin Xie (Since: 01 Apr 2011) TOP HOLDINGS (%) UNITEDHEALTH GROUP INC 5.79 PFIZER INC 5.07 ABBOTT LABORATORIES 4.03 STRYKER CORP 3.90 ASTRAZENECA PLC 3.88 MEDTRONIC PLC 3.87 BOSTON SCIENTIFIC CORP 3.50 NOVARTIS AG 3.44 SANOFI SA 2.74 JOHNSON & JOHNSON 2.50 Total 38.72 Holdings subject to change. Performance is calculated on a Net Asset Value (NAV) basis, with income reinvested, net of fees. Performance is calculated in the Fund s base currency, including ongoing charges and taxes and excluding subscription and redemption fees, if applicable. Benchmark performance displayed in denominated currency and for comparative purpose only. Source: BlackRock. Past performance is not a guide to future performance and should not be the sole factor of consideration when selecting a product. Investors may not get back the full amount invested. fund / offering
SECTOR BREAKDOWN (%) TOP COUNTRIES (%) Fund Benchmark Fund Benchmark Negative weightings may result from specific circumstances (including timing differences between trade and settlement dates of securities purchased by the funds) and/or the use of certain financial instruments, including derivatives, which may be used to gain or reduce market exposure and/or risk management. Allocations are subject to change. Due to rounding, the total may not be equal to 100 %. Geographic exposure relates principally to the domicile of the issuers of the securities held in the product, added together and then expressed as a percentage of the product s total holdings. However, in some instances it can reflect the country where the issuer of the securities carries out much of their business. Others excluded from the chart above. MARKET CAPITALISATION (%) PORTFOLIO CHARACTERISTICS Weighted Average Market Capitalisation (millions) 88,463.61 USD Price to Earnings Ratio 23.68x Price to Book Ratio 3.78x FEES AND CHARGES Max Initial Charge 5.00% Management Fee (incl. Distribution Fee, if any) 1.50% For Fee details, please refer to the Fund Prospectus. FUND FEATURES Flexible global health care equities portfolio aims to invest in best opportunities across all segments of the sector Managed by team with strong scientific experience in medicine Team spends a great deal of time studying clinical trial results and conducting field checks with physicians Fund Benchmark +852 3903 2688 clientservice.asiapac@blackrock.com www.blackrock.com/hk The Fund changed its investment policy and objective in 2017. Prior to this performance of the Fund was achieved under circumstances that no longer apply. Prior to 29 March 2017 the Fund was managed by Tom Callan and Erin Xie. Sources: BlackRock and Morningstar. Performance is shown as of the month end in share class currency on a NAV to NAV price basis with income reinvested, net of fees. The above Fund data is for information only and does not constitute an offer or invitation to anyone to invest in any BlackRock Global Funds (BGF) and has not been prepared in connection with any such offer. BGF is an open-ended investment company established in Luxembourg which is available for sale in certain jurisdictions only. BGF is not available for sale in the U.S. or to U.S. persons. Product information concerning BGF should not be published in the U.S. Investment involves risk. Past performance is not necessarily a guide to future performance or returns. The value of investments and the income from them can fluctuate and is not guaranteed. Rates of exchange may cause the value of investments to go up or down. Investors may not get back the amount they invest. Individual stock price/figure does not represent the return of the Fund. The investment returns are denominated in share class dealing currency, which may be a foreign currency. If so, US/HK dollar-based investors are therefore exposed to fluctuations in the US/HK dollar/foreign currency exchange rate. For Hong Kong investors, please refer to the BGF Prospectus for details, including risk factors. Issued by BlackRock Asset Management North Asia Limited. This material and the BlackRock website (www.blackrock.com/hk) have not been reviewed by the Securities and Futures Commission of Hong Kong. BlackRock is a registered trademark of BlackRock, Inc. 2018 BlackRock, Inc. All Rights Reserved. All other trademarks are those of their respective owners.
PRODUCT KEY FACTS BlackRock Global Funds World Healthscience Fund April 2018 BlackRock Asset Management North Asia Limited Quick facts This statement provides you with key information about this product This statement is a part of the offering document You should not invest in this product based on this statement alone Fund Manager: BlackRock (Luxembourg) S.A. Investment Advisers: BlackRock Investment Management, LLC (internal delegation, USA); BlackRock Investment Management (UK) Limited (internal delegation, UK) Depositary: The Bank of New York Mellon (International) Limited Ongoing charges Class A2 AUD Hedged 1.81% over a year: Class A2 EUR 1.81% Class A2 HKD Hedged 1.82% Class A2 SGD Hedged 1.82% Class A2 USD 1.81% Class C2 EUR 3.06% Class C2 USD 3.06% Class D2 EUR 1.07% Class D2 USD 1.07% Class D4 USD 1.07%* The ongoing charges figure for a class is based on the costs and expenses of that class with reference to the annual report of the Fund for the year ended 31 August 2017. For shares which are newly launched (marked *) the ongoing charges figure represents the Investment Adviser s best estimate of the ongoing charges based on the information available in respect of other active share classes with a similar fee structure. The figure may vary from year to year. Dealing frequency: Daily Financial year end: 31 August Base currency: USD Dividend policy: (Class A, C and D as at the above date) Non-Distributing Shares: No dividends will be declared or paid A2, C2, D2 Distributing Shares: Dividends, if declared will be paid in cash or reinvested Not Available Minimum investment: US$5,000 initial, US$1,000 additional for Class A and C Shares US$100,000 initial, US$1,000 additional for Class D Shares 334
BlackRock Global Funds World Healthscience Fund What is this product? This is a sub-fund of BlackRock Global Funds ( BGF ), an open-ended investment company incorporated in Luxembourg. Its home regulator is the Commission de Surveillance du Secteur Financier (CSSF). Objectives and Investment Strategy To maximise total return by investing at least 70% of the Fund s assets in stocks of companies worldwide with the majority of their business in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. The Fund may also invest in other emerging markets (such as Brazil, South Africa and South Korea). Subject to applicable regulatory restrictions and internal guidelines, the remaining 30% may be invested in financial instruments of companies or issuers of any size in any sector of the economy globally such as equity securities consistent with the Fund s objective and cash. The Fund may use derivatives for hedging, efficient portfolio management and investment purposes. However, derivatives will not be extensively or primarily used for investment purposes. The Fund may employ currency management and hedging techniques which may include hedging the currency exposure on the Fund's portfolio and/or using more active currency management techniques such as currency overlays. Any active management techniques implemented by the Fund through the currency derivatives such as forward exchange contracts, currency futures and options may not be correlated with the primary underlying securities held by the Fund. The proportion of the Fund s net asset value that is expected to be subject to securities lending transactions from time to time ranges from 0% to 40% and will be consistent with the overall investment policy of the Fund. What are the key risks? Investment involves risks. Please refer to the offering document for details including the risk factors. 1. Investment Risks The Fund is an investment fund. The Fund s investment portfolio may fall in value due to any of the risk factors below and therefore your investment in the Fund may suffer losses. 2. Equity Risk The values of equities fluctuate daily and a Fund investing in equities could incur significant losses. The price of equities can be influenced by many factors at the individual company level, as well as by broader economic and political developments, including changes in investment sentiment, trends in economic growth, inflation and interest rates, issuer-specific factors, corporate earnings reports, demographic trends and catastrophic events. 3. Limited Market Sectors Risks The Fund s investments are concentrated in the healthcare, pharmaceuticals and other healthscience sectors. This may subject the Fund to greater volatility and more rapid cyclical changes than more broad-based investments. 4. Currency Risks The Fund may invest in assets denominated in a currency other than the base currency of the Fund. Changes in exchange rates between such currency and the base currency and changes in exchange rate controls may adversely affect the value of the Fund s assets. The Investment Advisers may utilise techniques and instruments (e.g. currency overlays) in relation to currencies other than the base currency with the aim of generating positive returns. Any active currency management techniques implemented by the Fund may not be correlated with the underlying securities held by the Fund. As a result, the Fund may suffer significant losses even if there is no loss to the value of the underlying securities held by the Fund. 335
BlackRock Global Funds World Healthscience Fund 5. Derivatives Risks In an adverse situation, if the use of derivatives for hedging and efficient portfolio management becomes ineffective, the Fund may suffer significant losses. 6. Emerging Market Risks Investment in emerging markets may be subject to a higher than average volatility than more developed markets due to greater political, tax, economic, social, and foreign exchange risks. The size and trading volume of securities markets in emerging markets may be substantially smaller than developed markets. This may subject the Fund to higher liquidity and volatility risks. Custody and registration of assets in emerging markets may be less reliable than in developed markets, which may subject the Fund to higher settlement risk. The Fund may be subject to higher regulatory risks due to low level of regulation, enforcement of regulations and monitoring of investors activities in emerging markets. 7. Foreign Investments Restrictions Risks Some countries prohibit or restrict investment, or the repatriation of income, capital or the proceeds from sale of securities. The Fund may incur higher costs investing in these countries. Such restrictions may delay the investment or repatriation of capital of the Fund. 8. Small Cap Companies Risks Many small company stocks trade less frequently and in smaller volume, and may be subject to more abrupt or erratic price movements than stocks of large companies. The securities of small companies may also be more sensitive to market changes than the securities of large companies. 9. Securities Lending Risks When engaging in securities lending, the Fund will have a credit risk exposure to the counterparties to any securities lending contract. Fund investments can be lent to counterparties over a period of time. A default by the counterparty combined with a fall in the value of the collateral below that of the value of the securities lent may result in a reduction in the value of the Fund. 336
How has the Fund performed? Historic performance to 31 December 2017 50% 40% 30% 20% 10% 0% -10% -20% -30% BlackRock Global Funds World Healthscience Fund 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Fund -24.3 23.5 1.6 5.5 16.9 43.1 24.4 4.6-8.0 21.8 Benchmark -21.5 18.9 2.4 9.5 17.5 36.3 18.1 6.6-6.8 19.8 Notes: Past performance information is not indicative of future performance. You may not get back the full amount invested. The computation of the performance is based on the calendar year end, NAV-To-NAV, with dividend reinvested expressed as a % change. These figures show by how much the share class increased or decreased in value during the calendar year shown. Performance data has been calculated in USD, including ongoing charges and taxes and excluding subscription and redemption fees, if applicable. The past performance information reflects the performance of the A2 base currency share class which the Investment Advisers view as the most appropriate representative share class. Please refer to the website www.blackrock.com/hk for performance information regarding other share classes. This website has not been reviewed by the SFC. The benchmark of the Fund is MSCI World Health Care Index. Fund launch date: 2001 Share class launch date: 2001 Is there any guarantee? This Fund does not have any guarantees. You may not get back the full amount of money you invest. 337
BlackRock Global Funds World Healthscience Fund What are the fees and charges? Charges which may be payable by you You may have to pay the following fees when dealing in the shares of the Fund: Fee What you pay Subscription Fee Class A and Class D Shares: up to 5% of the price of shares (Initial Charge) Class C Shares: Nil Switching Fee Nil^, except a delayed Initial Charge of up to 5% of the price of Class A or (Conversion Charge) Class D Shares may be payable upon switching newly acquired Shares in a Reserve Fund into this Fund Redemption Fee Nil^ Contingent Deferred Class A and Class D Shares: Nil Sales Charge Class C Shares: 1% of the lower of the original investment amount or redemption proceeds if the Shares are held for less than one year ^ A 2% charge on redemptions/conversions may be levied where excessive trading by a shareholder is suspected. Ongoing fees payable by the Fund The following expenses paid by the Fund affect you because they reduce the return on your investments: Fee Management Fee Depositary Fees # Performance Fee What you pay (Annual rate) 1.50% of the net asset value of the relevant Class A and Class C Shares respectively* 0.75% of the net asset value of the relevant Class D Shares* Safekeeping fees: 0.0024% to 0.45% of the value of the securities Transactional fees: US$5.5 to US$124 per transaction Nil Administration Fee Up to 0.25% of the net asset value of the relevant share class* Distribution Fee Class A and Class D Shares: Nil Class C Shares: 1.25% of the net asset value of the relevant share class * May be increased to a combined 2.25% maximum upon giving three months prior notice to shareholders # Subject to change without prior notice Other fees You may have to pay other fees and charges when dealing in the shares of the Fund. Additional Information You generally buy and redeem shares at the Fund s next-determined price as long as the Hong Kong Representative receives your request in good order before the 6:00p.m. cut-off (HK time). Please check whether your distributor has an internal cut-off time which is earlier than this. The net asset value of the Fund is calculated daily. Prices of shares are published each business day on www.blackrock.com/hk. The website has not been reviewed by the SFC. The updated list of currently available shares is available from the Hong Kong Representative. Important If you are in doubt, you should seek professional advice. The SFC takes no responsibility for the contents of this statement and makes no representation as to its accuracy or completeness. 338